Related Experiment Video

Updated: Jun 26, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

PI3K inhibitors for cancer treatment: where do we stand?

Sauveur-Michel Maira1, Frédéric Stauffer, Christian Schnell

  • 1Novartis Institutes for Biomedical Research, Oncology Disease Area, Novartis Pharma AG, CH4002 Basel, Switzerland. sauveur-michel.maira@novartis.com

Biochemical Society Transactions
|January 16, 2009
PubMed

Insights

Targeted therapies, unlike cytotoxic agents, focus on cancer cells. This review updates on new phosphoinositide 3-kinase (PI3K) inhibitors, a promising targeted therapy for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapies offer improved specificity over traditional cytotoxic agents by focusing on cancer cells.
  • Tumorigenesis is driven by genetic alterations, making specific gene targets crucial for treatment.
  • The phosphoinositide 3-kinase (PI3K) pathway is frequently dysregulated in various human cancers.

Purpose of the Study:

  • To provide an update on novel phosphoinositide 3-kinase (PI3K) inhibitors in clinical development.
  • To discuss recent discoveries, challenges, and future prospects in PI3K-targeted cancer therapy.

Main Methods:

  • Review of current literature on PI3K inhibitors.
  • Analysis of clinical trial data for emerging PI3K-targeted agents.
  • Discussion of genetic alterations leading to PI3K pathway overactivation.

Main Results:

  • Identification of several new PI3K inhibitors advancing through clinical trials.
  • Overview of the genetic landscape driving PI3K pathway dysregulation in cancer.
  • Emerging data on the efficacy and safety profiles of these novel agents.

Conclusions:

  • PI3K inhibition represents a highly promising targeted therapy strategy for numerous cancers.
  • Ongoing research and development are expanding the arsenal of PI3K inhibitors.
  • Addressing challenges in clinical development will be key to realizing the full potential of PI3K-targeted treatments.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...